Svenska                Glossary                Search    
 
 
AboutTechnologyProjectInvestorMedia Releases 2010Contact
 
 
 
frontpage_pic3.png

   
Latest News Upcoming Events
   
   
Juni 22, 2010
NeuroNovas läkemedelskandidat sNN0029 för ALS får särläkemedelsstatus av amerikanska läkemedelsmyndigheten FDA
June 22, 2010
NeuroNova´s drug candidate sNN0029 for ALS/Lou Gehrig´s disease receives orphan drug designation by the FDA
 
Sept 22-25, 2010. European Society for Sterotactic and Functional Neurosurgery, Athens, Greece

Sept 25-28, 2010. European Federation of Neurological Societies (EFNS), Geneva, Switzerland.

Sept 28- Oct 1, 2010. World Parkinson Congress 2010, Glasgow, Scotland.

Nov 13- 17, 2010. Society for Neuroscience (SFN), San Diego, California, USA.


   
© NeuroNova AB, Sweden, Tel: +46 (0)8 786 0900, Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Sitemap   Site policy
Site last updated: Tuesday 22 June 2010  
 
 
Project Pipeline

Project

    Indication  

Pre-clin.

   IND  

 Phase I/II

 Phase II

 Phase III 

sNN0029ALS      
sNN0031Parkinson's disease     
More about our ProjectsImage

 Business Development

NeuroNova’s business strategy centers on developing novel therapeutic products based on neurogenesis in areas of high unmet medical need in neurodegenerative diseases.
More about business development.Image